Agent-assisted business development in early-stage life science companies

1. The assay: run it on your company

Eight questions, yes or no. Each answer loads one well. When all eight lanes are loaded, run the gel: every band drops onto what fixes it, and a band that stays in the well means that part of your business is fine.

2. Background

The people who can explain a bispecific antibody are rarely the people booking the meetings that fund one. In a typical early-stage company the commercial function is a founder's evenings: partner outreach happens after the experiments, licensing conversations stall for weeks between replies, and the company's public presence says less than its poster from last spring. Runway, meanwhile, does not pause.

Generalist agencies do not close this gap. They speak reach and impressions, not mechanisms and indications; a partnering conversation mishandled in the first sentence does not get a second one. The gap calls for commercial work that speaks science: a person who has pitched it, backed by agents built in-house to keep the repetitive work moving at the pace early-stage science actually demands.

3. Methods

Four services, each pairing conventional business development and marketing with agents built in-house: run individually or in sequence, configured to the company, its field, its stage, its wording. Every output passes a human referee before anything reaches a partner, an inbox or the public. Peer review, applied to your commercial work.

1. 3.1  Lead generation. Finds who is actually licensing, partnering or acquiring in your space, whether that is a pharma company, a CDMO, another startup or a university research group, then the named person there, and lands a shortlist with context on every name.
2. 3.2  Business development. Looks at the business model itself, splits what is proven from what is assumed, then names the buyer, the way in, and the order of moves that follow: a plan that holds when someone pushes back on it.
3. 3.3  Marketing audit. Six readings of your website and wider web presence: message, conversion path, technical health, search visibility, competitive position, and trust signals. Out comes a grade and a ranked list of fixes.
4. 3.4  Web presence. A site that speaks science and still sells: researched first, written second, designed last, fast on a phone.

4. Before the first call

We read before we talk. Our marketing audit agent (3.3) runs an initial screening of your online presence, and a person reviews it before we call, so the first call starts with findings, then covers how this works and whether it fits. Send your site and an email below, and book a time from about a day out.

5. Data availability & compliance

This page measures nothing without consent: analytics load only after an explicit yes, in line with Regulation (EU) 2016/679 [1], and the little data this page collects, a URL and an email, is used to read your site before the call, then for nothing else. We say this unprompted because we would rather you check than take our word.

6. Correspondence

About the corresponding author. Molecular biologist by training, BSc molecular biology and genetics, MSc translational research in biomedicine, then the commercial side of Envue Technologies through its acquisition in November 2025, and currently completing an MSc in business development and marketing. He has pitched science to KOLs and pharma partners for a living.

The first call is free, thirty minutes, no slides: how this works, whether it fits your company, and roughly what it costs. If nothing fits, we will say so. Prefer to write? support@aeormenlabs.com

Book the first call